Novo Nordisk has decided to keep a large-scale study investigating the cardiovascular benefits of obesity drug Wegovy (semaglutide) running, which could be to the chagrin of investors who hoped for results sooner rather than later.
In the pharmaceutical firm’s Q2 report from Wednesday, Novo Nordisk says that the external independent Data Monitoring Committee, DMC, recommended that the study continue back in July following a review of interim data. Consequently, the study will run as planned until mid-2023.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
ALK to exit Turkish market: "It's bad business if all we get is peanuts"
A number of conditions made it unfeasible for the Danish allergy firm to do business in Türkiye, says CEO Carsten Hellmann. Under a calculated and ruthless strategy to focus on markets with momentum, efforts in Italy and Spain have also been reduced.
Genmab postpones crucial cancer candidate decision following Abbvie exit
For the rest of 2022, the Danish biotech firm will share all expenses relating to the development of Duohexabody-CD37 with Abbvie, despite the US-based firm’s decision to withdraw from the collaboration in question.
Genmab says new arbitration builds on a straightforward question
”I think this is a much simpler case than the first arbitration,” says Genmab CEO Jan van de Winkel on the new legal suit brought against Janssen, which stems from a fight Genmab has already lost once.
Top news from MedWatch this week
Miss anything?
Analyst: Upgraded ALK sales guidance could still be beaten
Despite an upgrade, ALK may still beat its own sales guidance, one Sydbank analyst predicts.
Experienced Biostatistician 
Senior Manager, QA GCP/PV 
Medical Scientific Communications Manager 
QA Manager, QA Commercial Operations, Ascendis Pharma 
Senior Electronics Engineer 
Biomarker Operations Lead 
Senior Clinical Trial Manager - Black Swans Exist 
Director Regulatory Affairs 
Clinical Project Leader/ Sr. Clinical Trial Manager – make a difference and join our mission to bring our IL-22 lead program to patients 
Lead Auditor – Senior Quality Assurance Specialist 
Open position for a Clinical Trial Manager to join our team at Nykode! 
Scientist Radiochemistry